Continuous Glucose Monitors vs. A1C — Metabolic Clarity Labs

Continuous Glucose Monitors vs. A1C: What They Each Show That the Other Doesn't

A continuous glucose monitor and an A1C test can tell surprisingly different stories about the same person, and the gap between them is where the real information often lives.

By Charles Kirkland, Founder, Metabolic Clarity Labs
Updated August 2026

Quick answer: A1C reflects average glucose over roughly three months but hides day-to-day swings. A continuous glucose monitor (CGM) shows real-time glucose trends and calculates metrics like Time in Range and the Glucose Management Indicator (GMI), an estimated A1C. GMI and lab A1C often differ because they measure different things through different biological pathways, and it's genuinely possible to have an A1C under 7% while spending significant time in unsafe high or low glucose ranges that the A1C alone can't reveal.

Two fundamentally different measurement approaches

A1C measures how much glucose has attached to hemoglobin over the roughly 120-day lifespan of a red blood cell. It's a single number capturing a long average, and it says nothing about the shape of that average, whether it came from a stable pattern or from wild swings that happened to cancel out.

A CGM takes a completely different approach: it measures glucose in the fluid between your cells every one to five minutes, continuously, giving you a detailed picture of trends throughout the day and night rather than a single summarized number.

What GMI is, and why it isn't quite the same as A1C

The Glucose Management Indicator, or GMI, is a calculation that estimates what your lab A1C would likely be, based on your average CGM glucose readings over 10 to 14 days. It's calculated using a specific formula: GMI as a percentage equals 3.31 plus 0.02392 multiplied by your mean glucose in mg/dL.

GMI and your actual lab-measured A1C often differ, sometimes meaningfully. Differences between the two can reflect individual variation in red blood cell lifespan, how quickly glucose binds to your particular hemoglobin, or a recent shift in glucose control that hasn't fully shown up in the longer A1C average yet. It's worth knowing that GMI was originally developed and validated primarily in people with type 1 diabetes, and some more recent research has specifically questioned how reliable it is for people with type 2 diabetes, suggesting it should be interpreted cautiously in that population.

Time in Range: the metric A1C simply cannot provide

Time in Range, or TIR, is the percentage of time your glucose spends within a defined healthy range, commonly set at 70 to 180 mg/dL under the International Consensus on Time in Range. This is information A1C structurally cannot give you, since A1C only reports an average, not a distribution.

Here's the scenario that makes this concrete: it's genuinely possible to have significant time spent in unsafe low glucose ranges and substantial time in high ranges, while still landing at an A1C under 7%, the common target for many people with diabetes. The highs and lows can average out mathematically to a number that looks fine, while the actual day-to-day experience involves real swings the A1C never reveals.

Why the ADA recommends using both together

Current guidance doesn't frame this as CGM replacing A1C. The American Diabetes Association recommends assessing overall glucose control using A1C and CGM-derived metrics like Time in Range together, rather than picking one over the other. A1C remains useful for its convenience, its decades of research linking it to long-term complication risk, and its ability to summarize a long window without requiring continuous device wear. CGM metrics add the day-to-day texture and variability picture that A1C was never designed to provide.

Limitations that apply to CGM data too

CGM isn't without its own caveats. For GMI and Time in Range to be considered reliable, the device generally needs to be worn more than 70% of the time over at least 14 days; inconsistent wear undermines the reliability of both metrics. CGM measures glucose in interstitial fluid rather than blood directly, which can create small timing lags compared with a blood draw, particularly during rapid glucose changes.

What this means for how you use each tool

Use A1C for the long-term summary your clinician will use to assess overall risk and guide major treatment decisions over months.

Use CGM-derived Time in Range and glucose trends to understand your day-to-day pattern, including whether specific meals, activities, or times of day are driving swings that a single average would hide.

If your GMI and lab A1C disagree meaningfully, don't assume one is simply wrong; discuss the discrepancy with your clinician, since the gap itself can be informative.

Don't use CGM wear time inconsistently and then treat the resulting GMI as equivalent to a properly measured, minimum-duration reading.

Frequently asked questions

Can I use GMI instead of getting an A1C blood test?

Not as a full substitute. GMI is an estimate derived from CGM data, and it doesn't replace laboratory-measured A1C, particularly since research on its reliability in type 2 diabetes specifically is still evolving.

Why don't my GMI and lab A1C match?

This is a recognized, common occurrence. Individual differences in red blood cell lifespan and glycation rate, along with recent changes in glucose control not yet reflected in the longer A1C average, can all create a gap between the two numbers.

Is Time in Range more important than A1C?

They answer different questions rather than competing for importance. A1C summarizes long-term average exposure; Time in Range shows the daily pattern and variability that the average alone can hide. Current guidance supports using both.

How much CGM wear time do I need for accurate metrics?

Commonly cited guidance suggests wearing the device more than 70% of the time over at least 14 days for GMI and Time in Range to be considered reliable.

Can I have a good A1C and still have a problem?

Yes. It's possible to have significant time in unsafe high or low glucose ranges while still averaging out to an A1C in your target range, which is exactly why Time in Range data can reveal something A1C alone cannot.

The Metabolic Clarity takeaway

A1C and CGM data aren't competing answers to the same question; they're answers to two different questions. One tells you the long-term average. The other tells you the shape of the days that produced it. The most complete picture uses both.

Next step: Read the complete guide to A1C to understand what your lab result does and doesn't capture, then discuss with your clinician whether CGM-derived metrics would add useful detail to your specific situation.

Sources

Charles Kirkland is the founder of Metabolic Clarity Labs. He is not a physician. His writing is based on his own documented health experience, alongside cited research sources.

Medical and regulatory disclaimer: This article is for general education only. It does not diagnose, treat, or prevent disease and does not replace advice from a physician or other qualified health professional. Do not start, stop, or change a diabetes medication based on this article. Seek prompt medical care for symptoms of very high or very low blood glucose, including confusion, severe weakness, fainting, or difficulty breathing.

Back to blog